| Field | Specification |
|---|---|
| Gene ID | |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Applications | |
| Conjugate | |
| Concentration | |
| Storage | |
| Storage buffer | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
Validated Applications & Recommended Dilutions
| Application | Recommended Dilution |
|---|---|
| Flow Cytometry | See product datasheet |
| Immunophenotyping | See product datasheet |
Antibody Specifications
| Target | IFNγ |
|---|---|
| Host Species | Rat |
| Clonality | Monoclonal |
| Isotype | Rat IgG1, κ |
| Conjugate | FITC |
| Clone Number | XMG1.2 |
| Purification | See datasheet |
| Concentration | 5 μL/Test |
Immunogen
Recombinant protein fragment; see full datasheet. UniProt: P01580.
Species Reactivity & Cross-Reactivity
Validated for: Mouse. Verify suitability in your sample type prior to use. For species or applications not listed in the datasheet, consult our technical team before purchase.
Storage & Handling
This product can be stored at 2-8°C for 12 months. Please protected from prolonged exposure to light and do not freeze.
Storage Buffer: Phosphate buffered solution, pH 7.2, containing 0.09% stabilizer and 1% protein protectant.
Related Products
Browse additional antibodies targeting IFNγ and complementary reagents — including secondary antibodies, blocking buffers, and detection kits — available through BioHippo.
Yes — this antibody is validated for both surface and intracellular flow cytometry. For intracellular targets, fix and permeabilize cells using a validated fixation/permeabilization kit (e.g., BD Cytofix/Cytoperm or similar) before staining. For surface markers, stain live or fixed cells without permeabilization. Always include a matched isotype control (Rat IgG1, κ, Rat origin) at the same protein concentration as the test antibody to establish non-specific binding thresholds. Recommended starting dilution/concentration: see datasheet.
This antibody has been experimentally validated in: Mouse. Cross-reactivity with other species has not been systematically evaluated. If your sample species is not listed, assess immunogen sequence homology to your target species ortholog. The immunogen used is: "" — higher sequence identity between species increases the probability of cross-reactivity, but experimental validation with appropriate controls is necessary before drawing scientific conclusions.
This product can be stored at 2-8°C for 12 months. Please protected from prolonged exposure to light and do not freeze. Storage Buffer: Phosphate buffered solution, pH 7.2, containing 0.09% stabilizer and 1% protein protectant.. To maintain antibody activity, avoid repeated freeze-thaw cycles. Aliquot into single-use volumes before first freeze. If working with the antibody frequently, keep a working stock at 4°C for up to 4 weeks — add 0.02% sodium azide to the working stock as a bacteriostatic agent if azide is not already present in the buffer. Monitor performance against a validated positive control when transitioning between storage aliquots or lots.
This monoclonal antibody (clone XMG1.2) provides highly consistent, epitope-specific recognition of IFNγ, making it ideal for quantitative assays, multiplex panels, and studies requiring strict reproducibility across experiments and independent laboratories. Unlike polyclonal preparations, each production batch from a single hybridoma clone generates antibody with identical epitope specificity, affinity, and isotype — ensuring reliable signal comparison in longitudinal studies or multi-site collaborations. When citing this antibody in publications, include the clone designation (clone XMG1.2) to enable third-party reproducibility verification.
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
A Bionic Yeast Tumor Vaccine Using the Co-Loading Strategy to Prevent Post-Operative Tumor Recurrence (2023) ACS Nano. 10.1021/acsnano.3c06115
Radiotherapy-Triggered In Situ Tumor Vaccination Boosts Checkpoint Blockaded Immune Response via Antigen-Capturing Nanoadjuvants (2023) ACS Nano. 10.1021/acsnano.3c10225
Utilizing Engineered Bacteria as “Cell Factories” In Vivo for Intracellular RNA-Loaded Outer Membrane Vesicles’ Self-Assembly in Tumor Treatment (2024) ACS Nano. 10.1021/acsnano.4c11412
Optically controllable nanoregulators enable tumor-specific pro-ferroptosis lipometabolic reprogramming for in-situ adjuvant-free vaccination (2025) BIOMATERIALS. 10.1016/j.biomaterials.2025.123096
Radiation-triggerable bioreactors enable bioenergetic reprograming of cancer stem cell plasticity via targeted arginine metabolism disruption for augmented radio-immunotherapy (2025) BIOMATERIALS. 10.1016/j.biomaterials.2025.123391
Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer (2025) JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 10.1186/s13046-025-03464-x
Chemical activation of mitochondrial ClpP to modulate energy metabolism of CD4+ T?cell for inflammatory bowel diseases treatment (2024) Cell Reports Medicine. 10.1016/j.xcrm.2024.101840
Targeting RRBP1 reverses immune evasion and enhances immunotherapy efficacy via the CXCL10-CXCR3 axis in bladder cancer (2026) Journal for ImmunoTherapy of Cancer. 10.1136/jitc-2025-013809
Bionic gene delivery system activates tumor autophagy and immunosuppressive niche to sensitize anti-PD-1 treatment against STK11-mutated lung adenocarcinoma (2025) JOURNAL OF NANOBIOTECHNOLOGY. 10.1186/s12951-025-03404-z
Amplifying STING activation by biomimetic manganese mRNA nanovaccines for local and systemic cancer immunotherapy (2025) JOURNAL OF CONTROLLED RELEASE. 10.1016/j.jconrel.2025.113788
Antigen-Enriched Tumor-Dendritic Cell Fusion Membrane-Coated Metal-Phenolic Nanovaccine Enables Dual T-Cell Activation for Robust Cancer Immunotherapy (2026) Advanced Healthcare Materials. 10.1002/adhm.202505255
NIR-activated Janus nanomotors with promoted tumor permeability for synergistic photo-immunotherapy (2024) Acta Biomaterialia. 10.1016/j.actbio.2024.10.040
Low-fluence laser-facilitated platelet-rich plasma permeation for treating MRSA-infected wound and photoaging of the skin (2021) INTERNATIONAL JOURNAL OF PHARMACEUTICS. 10.1016/j.ijpharm.2021.120242
